These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 39164479)

  • 1. CD4
    Borcherding N; Kim W; Quinn M; Han F; Zhou JQ; Sturtz AJ; Schmitz AJ; Lei T; Schattgen SA; Klebert MK; Suessen T; Middleton WD; Goss CW; Liu C; Crawford JC; Thomas PG; Teefey SA; Presti RM; O'Halloran JA; Turner JS; Ellebedy AH; Mudd PA
    Nat Immunol; 2024 Sep; 25(9):1731-1741. PubMed ID: 39164479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.
    Essink BJ; Shapiro C; Isidro MGD; Bradley P; Pragalos A; Bloch M; Santiaguel J; Frias MV; Miyakis S; Alves de Mesquita M; Berrè S; Servais C; Waugh N; Hoffmann C; Baba E; Schönborn-Kellenberger O; Wolz OO; Koch SD; Ganyani T; Boutet P; Mann P; Mueller SO; Ramanathan R; Gaudinski MR; Vanhoutte N
    Hum Vaccin Immunother; 2024 Dec; 20(1):2408863. PubMed ID: 39422261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polysaccharide, Conjugate, and mRNA-based Vaccines are Immunogenic in Patients with Netherton Syndrome.
    Nouwen AEM; Zaeck LM; Schappin R; Geers D; Gommers L; Bogers S; Dik WA; Pasmans SGMA; GeurtsvanKessel CH; de Vries RD; Dalm VASH
    J Clin Immunol; 2024 Oct; 45(1):36. PubMed ID: 39476295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody response to SARS-CoV-2 mRNA vaccination in Danish adults exposed to perfluoroalkyl substances (PFASs): The ENFORCE study.
    Timmermann A; Johansen IS; Tolstrup M; Heilmann C; Budtz-Jørgensen E; Tolstrup JS; Nielsen F; Grandjean P
    Environ Res; 2024 Dec; 263(Pt 1):120039. PubMed ID: 39326653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees.
    Geers D; Shamier MC; Bogers S; den Hartog G; Gommers L; Nieuwkoop NN; Schmitz KS; Rijsbergen LC; van Osch JAT; Dijkhuizen E; Smits G; Comvalius A; van Mourik D; Caniels TG; van Gils MJ; Sanders RW; Oude Munnink BB; Molenkamp R; de Jager HJ; Haagmans BL; de Swart RL; Koopmans MPG; van Binnendijk RS; de Vries RD; GeurtsvanKessel CH
    Sci Immunol; 2021 May; 6(59):. PubMed ID: 34035118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe acute respiratory syndrome coronavirus 2-specific T-cell responses are induced in people living with human immunodeficiency virus after booster vaccination.
    Wang X; Li Y; Jin J; Chai X; Ma Z; Duan J; Zhang G; Huang T; Zhang X; Zhang T; Wu H; Cao Y; Su B
    Chin Med J (Engl); 2024 Nov; 137(22):2734-2744. PubMed ID: 39028115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women.
    Collier AY; McMahan K; Yu J; Tostanoski LH; Aguayo R; Ansel J; Chandrashekar A; Patel S; Apraku Bondzie E; Sellers D; Barrett J; Sanborn O; Wan H; Chang A; Anioke T; Nkolola J; Bradshaw C; Jacob-Dolan C; Feldman J; Gebre M; Borducchi EN; Liu J; Schmidt AG; Suscovich T; Linde C; Alter G; Hacker MR; Barouch DH
    JAMA; 2021 Jun; 325(23):2370-2380. PubMed ID: 33983379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age differentially impacts adaptive immune responses induced by adenoviral versus mRNA vaccines against COVID-19.
    Dallan B; Proietto D; De Laurentis M; Gallerani E; Martino M; Ghisellini S; Zurlo A; Volpato S; Govoni B; Borghesi M; Albanese V; Appay V; Bonnini S; Llewellyn-Lacey S; Pacifico S; Grumiro L; Brandolini M; Semprini S; Sambri V; Ladell K; Parry HM; Moss PAH; Price DA; ; Caputo A; Gavioli R; Nicoli F
    Nat Aging; 2024 Aug; 4(8):1121-1136. PubMed ID: 38918602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam.
    Duc Dang A; Dinh Vu T; Hai Vu H; Thanh Ta V; Thi Van Pham A; Thi Ngoc Dang M; Van Le B; Huu Duong T; Van Nguyen D; Lawpoolsri S; Chinwangso P; McLellan JS; Hsieh CL; Garcia-Sastre A; Palese P; Sun W; Martinez JL; Gonzalez-Dominguez I; Slamanig S; Manuel Carreño J; Tcheou J; Krammer F; Raskin A; Minh Vu H; Cong Tran T; Mai Nguyen H; Mercer LD; Raghunandan R; Lal M; White JA; Hjorth R; Innis BL; Scharf R
    Vaccine; 2022 Jun; 40(26):3621-3632. PubMed ID: 35577631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.
    Collier DA; De Marco A; Ferreira IATM; Meng B; Datir RP; Walls AC; Kemp SA; Bassi J; Pinto D; Silacci-Fregni C; Bianchi S; Tortorici MA; Bowen J; Culap K; Jaconi S; Cameroni E; Snell G; Pizzuto MS; Pellanda AF; Garzoni C; Riva A; ; Elmer A; Kingston N; Graves B; McCoy LE; Smith KGC; Bradley JR; Temperton N; Ceron-Gutierrez L; Barcenas-Morales G; ; Harvey W; Virgin HW; Lanzavecchia A; Piccoli L; Doffinger R; Wills M; Veesler D; Corti D; Gupta RK
    Nature; 2021 May; 593(7857):136-141. PubMed ID: 33706364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary series COVID-19 vaccine effectiveness among health care workers in the country of Georgia, March-December 2021.
    Katz MA; Rojas Castro MY; Chakhunashvili G; Chitadze N; Ward CL; McKnight CJ; Lucaccioni H; Finci I; Zardiashvili T; Pebody R; Kissling E; Sanodze L
    PLoS One; 2024; 19(9):e0307805. PubMed ID: 39240827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 vaccination survey and anti-SARS-CoV-2 IgG responses in a human cohort from
    Niu M; Mu Y; Adriko M; Candia R; Jones MK; McManus DP; Egwang TG; Cai P
    Front Public Health; 2024; 12():1437063. PubMed ID: 39624416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced mucosal SARS-CoV-2 immunity after heterologous intramuscular mRNA prime/intranasal protein boost vaccination with a combination adjuvant.
    Laghlali G; Wiest MJ; Karadag D; Warang P; O'Konek JJ; Chang LA; Park SC; Yan V; Farazuddin M; Janczak KW; García-Sastre A; Baker JR; Wong PT; Schotsaert M
    Mol Ther; 2024 Dec; 32(12):4448-4466. PubMed ID: 39489918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of antibody responses of heterologous and homologous Covid-19 booster vaccination: an observational study.
    Rizvi NB; Bibi M; Rana MZ; Zaffar S; Farooq H
    Front Immunol; 2024; 15():1448408. PubMed ID: 39606247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trimerized S expressed by modified vaccinia virus Ankara (MVA) confers superior protection against lethal SARS-CoV-2 challenge in mice.
    Zhu J; Wang Z; Li Y; Zhang Z; Ren S; Wang J; Xie S; Liao Z; Song B; Wu W; Yan F; Peng C
    J Virol; 2024 Jul; 98(7):e0052124. PubMed ID: 38874361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methotrexate treatment hampers induction of vaccine-specific CD4 T cell responses in patients with IMID.
    Kummer LYL; Fernández Blanco L; Kreher C; Bos A; Kuijper LH; Verstegen NJM; van de Sandt CE; Konijn VAL; Duurland MC; Menage C; Jorritsma T; Steenhuis M; Hagen RR; van den Dijssel J; de Jongh R; Ashhurst T; van Gils MJ; Garcia-Vallejo JJ; Claireaux M; Stalman EW; van Dam KPJ; Wieske L; Boekel L; Wolbink G; Tas SW; Rispens T; Kuijpers TW; Eftimov F; van Ham SM; Ten Brinke A;
    RMD Open; 2024 Oct; 10(4):. PubMed ID: 39375177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvants to the S1-subunit of the SARS-CoV-2 spike protein vaccine improve antibody and T cell responses and surrogate neutralization in mice.
    Becker W; Rebbani K; Duan Z; Valkov E; Bryant S; Ho M; Berzofsky JA; Olkhanud PB
    Sci Rep; 2024 Nov; 14(1):29609. PubMed ID: 39609527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.
    Richardson SI; Mzindle N; Motlou T; Manamela NP; van der Mescht MA; Lambson BE; Everatt J; Amoako DG; Balla S; von Gottberg A; Wolter N; de Beer Z; de Villiers TR; Bodenstein A; van den Berg G; Abdullah F; Rossouw TM; Boswell MT; Ueckermann V; Bhiman JN; Moore PL
    J Virol; 2024 Jul; 98(7):e0067824. PubMed ID: 38953380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
    Liu X; Munro APS; Wright A; Feng S; Janani L; Aley PK; Babbage G; Baker J; Baxter D; Bawa T; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Fox L; Qureshi E; Goodman AL; Green CA; Haughney J; Hicks A; Jones CE; Kanji N; van der Klaauw AA; Libri V; Llewelyn MJ; Mansfield R; Maallah M; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Belhadef HT; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Saralaya D; Sharma S; Sheridan R; Stokes M; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Cornelius V; Snape MD; Faust SN;
    J Infect; 2023 Jul; 87(1):18-26. PubMed ID: 37085049
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.